Rilotumumab
Information
- Drug Name
- Rilotumumab
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| stomach carcinoma |
MET OVEREXPRESSION ( ENST00000318493.11 ) MET OVEREXPRESSION ( ENST00000318493.11 ) |
B |
Predictive
|
Does Not Support
|
Sensitivity/Response |
N/A
|
5 | 28958504 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In this randomised, double-blind, placebo-controll... | MET |
MET OVEREXPRESSION ( ENST00000318493.11 ) MET OVEREXPRESSION ( ENST00000318493.11 ) |
Sensitivity | false | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00788957 | Completed | Phase 1/Phase 2 | Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) | October 2008 | October 2013 |
| NCT01039207 | Completed | Phase 2 | Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | October 2010 | July 2014 |
| NCT01791374 | Completed | Phase 1 | Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ | November 2012 | March 2015 |
| NCT02154490 | Completed | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | July 8, 2014 | April 15, 2022 | |
| NCT02926638 | Terminated | Phase 2/Phase 3 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | June 16, 2014 | October 12, 2016 |
| NCT02137343 | Terminated | Phase 3 | A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer | July 2014 | June 2015 |
| NCT01697072 | Terminated | Phase 3 | First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma | October 2012 | August 2015 |
| NCT01105390 | Withdrawn | Phase 2 | AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma | April 2010 |